Biodrug Suppresses Breast and Colorectal Cancer in Murine Models
RNA interference (RNAi) remains one of the most promising and emerging strategies for the effective cancer treatment due to its high target specificity and greater potency. However, it is hindered due to lack of appropriate targeting technologies. Therefore, there is an imminent need to develop specific and robust delivery systems for successful gene silencing. Nanotechnology-based strategies have been in place to combat the shortcomings associated with viral-based delivery systems. Herein we describe protocols for successful in vitro and in vivo delivery of gene-specific nucleic acids such as siRNAs and shRNAs using PEI-PGMA nanoparticles for efficient cancer therapy.
KeywordsRNA interference Gene silencing Nanoparticles Cancer therapy
We acknowledge all authors of original publication for their respective contribution to the original manuscript from where this protocol is derived.
- 10.Moghimi SM, Symonds P, Murray JC, Hunter AC, Debska G, Szewczyk A (2005) A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. MolTher 11:990–995Google Scholar
- 11.Grzelinski M, Urban-Klein B, Martens T, Lamszus K, Bakowsky U, Hobel S et al (2006) RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther 17:751–766CrossRefPubMedGoogle Scholar